Aspire Biopharma Holdings (ASBP) Total Debt (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Total Debt for 5 consecutive years, with $499214.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Debt fell 88.62% year-over-year to $499214.0 in Q1 2026; TTM through Mar 2026 was $499214.0, a 88.62% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, down 80.42% from the prior year.
• Total Debt was $499214.0 for Q1 2026 at Aspire Biopharma Holdings, down from $3.0 million in the prior quarter.
• Over five years, Total Debt peaked at $15.5 million in Q4 2024 and troughed at $385404.0 in Q4 2023.
• A 4-year average of $4.9 million and a median of $4.7 million in 2025 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 3928.92% in 2024 and plunged 88.62% in 2026, its largest moves.
• Over 4 years, Total Debt stood at $385404.0 in 2023, then jumped by 3928.92% to $15.5 million in 2024, then sank by 80.42% to $3.0 million in 2025, then slumped by 83.58% to $499214.0 in 2026.
• The last three Total Debt figures came in at $499214.0 (Q1 2026), $3.0 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.